āĻšā§āĻŽMOLN âĸ NASDAQ
add
Molecular Partners AG
ā§Š.ā§ā§Ģ$
āĻĒā§āĻ°āĻŋ-āĻŽāĻžāĻ°ā§āĻā§āĻ:(ā§Ž.ā§Ļā§%)+ā§Ļ.ā§Šā§Ļ
ā§Ē.ā§Ļā§Ģ$
āĻŦāĻ¨ā§āĻ§ āĻāĻā§: ā§¨ āĻŽā§, ā§Ŧ:ā§Ģā§Ļ:ā§§ā§¯ AM GMT -ā§Ē · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§Š.ā§¯ā§§$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§Š.ā§Ŧā§Š$ - ā§Š.ā§Žā§Ŧ$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§Š.ā§Šā§Ŧ$ - ā§§ā§¨.ā§ā§Ļ$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§§ā§Ģ.ā§Ēā§Â āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§§ā§Ž.ā§Žā§Ŧ āĻšāĻž
āĻŦāĻžāĻāĻžāĻ° āĻ¸āĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (CHF) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ļ.ā§Ļā§Ļ | -ā§§ā§Ļā§Ļ.ā§Ļā§Ļ% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§Ģā§Š.ā§Ēā§Ģ āĻ˛āĻž | -ā§.ā§Šā§% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§.ā§§ā§¨Â āĻā§ | ā§Ēā§Š.ā§¨ā§¨% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | â | â |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | -ā§Ļ.ā§Šā§Ļ | â |
EBITDA | -ā§§.ā§Ēā§Ģ āĻā§ | ā§§ā§§.ā§Šā§¯% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | -ā§Ļ.ā§Ļā§¨% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (CHF) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§§ā§Ē.ā§¯ā§Ē āĻā§ | -ā§¨ā§Ļ.ā§Ļā§Ē% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§§ā§Ģ.ā§Žā§Ģ āĻā§ | -ā§¨ā§Ļ.ā§Ļā§Ž% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§§.ā§Ŧā§¯Â āĻā§ | -ā§¨ā§¨.ā§¯ā§Ģ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§Ē.ā§§ā§Ŧ āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Š.ā§Ŧā§¯Â āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§§.ā§Ļā§¨ | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§¨ā§Š.ā§Ŧā§Ģ% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | -ā§¨ā§Ģ.ā§¯ā§Ļ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (CHF) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§.ā§§ā§¨Â āĻā§ | ā§Ēā§Š.ā§¨ā§¨% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | -ā§§.ā§Šā§¨Â āĻā§ | ā§§ā§.ā§Ēā§% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§Ēā§Ē.ā§¯ā§Ē āĻ˛āĻž | -ā§§ā§¨ā§Š.ā§§ā§Ļ% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§§.ā§Ģā§ŠÂ āĻā§ | ā§Ģ,ā§¨ā§Šā§Ē.ā§Ģā§Ŧ% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§§ā§Ž.ā§ā§ŽÂ āĻ˛āĻž | -ā§ā§¨.ā§¨ā§¯% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | -ā§Ŧā§Š.ā§Šā§ŽÂ āĻ˛āĻž | ā§Šā§¨.ā§¨ā§Ž% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Molecular Partners AG is a clinical-stage biopharmaceutical company based in ZÃŧrich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§Ļā§Ļā§Ē
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§§ā§Ģā§¯
